NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free VVOS Stock Alerts $4.47 -0.03 (-0.67%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$4.46▼$4.7750-Day Range$4.26▼$9.4552-Week Range$2.73▼$48.79Volume59,083 shsAverage Volume125,426 shsMarket Capitalization$5.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vivos Therapeutics alerts: Email Address Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesMarch 15, 2024 | americanbankingnews.comVivos Therapeutics (NASDAQ:VVOS) and Biotricity (NASDAQ:BTCY) Head-To-Head AnalysisMarch 14, 2024 | americanbankingnews.comShort Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Declines By 19.2%March 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesFebruary 18, 2024 | investing.comVivos Therapeutics secures $4 million through warrant exerciseFebruary 15, 2024 | finance.yahoo.comVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsFebruary 15, 2024 | proactiveinvestors.comVivos Therapeutics sees gross proceeds of $4M from exercise of warrantMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 12, 2024 | finance.yahoo.comVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsFebruary 6, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesFebruary 6, 2024 | finance.yahoo.comVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesJanuary 8, 2024 | finance.yahoo.comVivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSADecember 11, 2023 | proactiveinvestors.comVivos Therapeutics announces women-led airway health eventDecember 11, 2023 | finance.yahoo.comVivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”December 1, 2023 | proactiveinvestors.comVivos Therapeutics severe sleep apnea treatment’s a ‘breakthrough’, says CEONovember 30, 2023 | benzinga.comThinking about buying stock in Minim Inc, Walmart, Farfetch Ltd, Qualcomm, or Vivos Therapeutics Inc?November 30, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Down 35% Today?November 30, 2023 | msn.comPhilips shares slump as FDA says sleep product may overheatNovember 29, 2023 | proactiveinvestors.comVivos Therapeutics: Who is the medical device company creating frenzy in the markets?November 29, 2023 | proactiveinvestors.comVivos Therapeutics receives first ever FDA 510(k) clearance...Vivos Therapeutics receives first ever FDA 510(k) clearance for...November 29, 2023 | msn.comVivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearanceNovember 29, 2023 | finance.yahoo.comUPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apneaNovember 29, 2023 | finance.yahoo.comVivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apneaNovember 29, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 290% Today?November 29, 2023 | reuters.comUS FDA clears Vivos Therapeutics' oral device treatment for sleep apneaNovember 29, 2023 | markets.businessinsider.comVivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep ApneaSee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/18/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,840,000.00 Net Margins-106.28% Pretax Margin-106.27% Return on Equity-508.27% Return on Assets-129.15% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$16.02 million Price / Sales0.37 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book0.93Miscellaneous Outstanding Shares1,330,000Free Float1,204,000Market Cap$5.95 million OptionableOptionable Beta8.04 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 66)Co-Founder, Chairman of the Board & CEO Comp: $454.05kMr. Bradford K. Amman (Age 62)CFO, Treasurer & Secretary Comp: $297.23kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder & Executive VP of OperationsMs. Julie GannonSenior VP of Strategic Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical Integration DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of Dental Service IntegrationMr. John BallardSenior Vice President of TechnologyMore ExecutivesKey CompetitorsGlucoTrackNASDAQ:GCTKMinerva SurgicalNASDAQ:UTRSAcutus MedicalNASDAQ:AFIBPlus TherapeuticsNASDAQ:PSTVNeuroMetrixNASDAQ:NUROView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 604,436 shares on 3/11/2024Ownership: 0.795%Vanguard Group Inc.Sold 604,436 shares on 2/15/2024Ownership: 0.794%Armistice Capital LLCBought 57,000 shares on 2/13/2024Ownership: 4.286%Strategic Wealth Investment Group LLCSold 3,090,916 shares on 1/16/2024Ownership: 9.683%Ronald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)View All Insider TransactionsView All Institutional Transactions VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed in 2024? Vivos Therapeutics' stock was trading at $12.44 at the start of the year. Since then, VVOS shares have decreased by 64.1% and is now trading at $4.47. View the best growth stocks for 2024 here. Are investors shorting Vivos Therapeutics? Vivos Therapeutics saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 23,600 shares, a decrease of 19.2% from the February 14th total of 29,200 shares. Based on an average trading volume of 187,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.1% of the shares of the company are sold short. View Vivos Therapeutics' Short Interest. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) issued its quarterly earnings results on Monday, November, 15th. The company reported ($6.50) earnings per share for the quarter, missing the consensus estimate of ($4.00) by $2.50. The company had revenue of $4.55 million for the quarter, compared to analyst estimates of $4.50 million. Vivos Therapeutics had a negative net margin of 106.28% and a negative trailing twelve-month return on equity of 508.27%. When did Vivos Therapeutics' stock split? Vivos Therapeutics shares reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. Who are Vivos Therapeutics' major shareholders? Vivos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Strategic Wealth Investment Group LLC (9.68%), Armistice Capital LLC (4.29%), Vanguard Group Inc. (0.80%), Vanguard Group Inc. (0.79%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman. View institutional ownership trends. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.